Letter to the Editor: Author reply to Letter to the Editor regarding ‘The physical health and premature mortality of Indigenous Māori following first-episode psychosis diagnosis: A 15-year follow-up study’
Restricted accessLetterFirst published online March, 2025
Letter to the Editor: Author reply to Letter to the Editor regarding ‘The physical health and premature mortality of Indigenous Māori following first-episode psychosis diagnosis: A 15-year follow-up study’
EfthimiouOTaipaleHRaduaJ, et al. (2024) Efficacy and effectiveness of antipsychotics in schizophrenia: Network meta-analyses combining evidence from randomised controlled trials and real-world data. The Lancet: Psychiatry11: 102–111.
2.
GalletlyCCastleDDarkF, et al. (2016) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry50: 410–472.
3.
KomossaKKlugeCHungerH, et al. (2010) Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2010: CD006654.
4.
SolmiMTiihonenJLähteenvuoM, et al. (2022) Antipsychotics use is associated with greater adherence to cardiometabolic medications in patients with schizophrenia: Results from a nationwide within-subject design study. Schizophrenia Bulletin48: 166–175.
5.
TaipaleHTanskanenAMehtäläJ, et al. (2020). 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry: Official Journal of the World Psychiatric Association19: 61–68.
